This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021
Launches FSSAI’s inclusive campaign to stop obesity with multilingual, sign language outreach and multi-platform media engagement under Eat Right India programme
Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with Spinal Muscular Atrophy (SMA)
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer
Approximately 35% of male cancer patients and 12% of female cancer patients at Paras Health were diagnosed with tobacco-related cancers
The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance
Subscribe To Our Newsletter & Stay Updated
